0001140361-17-001832.txt : 20170113 0001140361-17-001832.hdr.sgml : 20170113 20170113161522 ACCESSION NUMBER: 0001140361-17-001832 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170111 FILED AS OF DATE: 20170113 DATE AS OF CHANGE: 20170113 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9143477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 17527897 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 form4.xml FORM 4 X0306 4 2017-01-11 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54 RUE LA BOETIE PARIS I0 75008 FRANCE true Common Stock 2017-01-11 4 P 0 1592 362.4664 A 23419988 I See note Common Stock 2017-01-11 4 P 0 6546 363.3534 A 23426534 I See note Common Stock 2017-01-11 4 P 0 13226 364.3224 A 23439760 I See note Common Stock 2017-01-11 4 P 0 19858 365.2018 A 23459618 I See note Common Stock 2017-01-11 4 P 0 3979 366.0528 A 23463597 I See note Common Stock 2017-01-11 4 P 0 1986 367.2911 A 23465583 I See note Common Stock 2017-01-11 4 P 0 2336 368.3472 A 23467919 I See note Common Stock 2017-01-11 4 P 0 2517 369.3 A 23470436 I See note Common Stock 2017-01-11 4 P 0 900 370.1789 A 23471336 I See note Common Stock 2017-01-11 4 P 0 1259 371.5346 A 23472595 I See note Common Stock 2017-01-11 4 P 0 2675 372.8741 A 23475270 I See note Common Stock 2017-01-11 4 P 0 2784 373.9018 A 23478054 I See note Common Stock 2017-01-11 4 P 0 3830 374.5922 A 23481884 I See note Common Stock 2017-01-11 4 P 0 3016 375.8789 A 23484900 I See note Common Stock 2017-01-11 4 P 0 3851 376.7488 A 23488751 I See note Common Stock 2017-01-11 4 P 0 5313 377.8368 A 23494064 I See note Common Stock 2017-01-11 4 P 0 9520 378.7635 A 23503584 I See note Common Stock 2017-01-11 4 P 0 2110 379.5636 A 23505694 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $361.76 to $362.71 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors. Purchase prices range from $362.80 to $363.79 per share, inclusive. Purchase prices range from $363.80 to $364.77 per share, inclusive. Purchase prices range from $364.80 to $365.79 per share, inclusive. Purchase prices range from $365.80 to $366.73 per share, inclusive. Purchase prices range from $366.83 to $367.81 per share, inclusive. Purchase prices range from $367.84 to $368.78 per share, inclusive. Purchase prices range from $368.84 to $369.79 per share, inclusive. Purchase prices range from $369.87 to $370.59 per share, inclusive. Purchase prices range from $371.05 to $372.02 per share, inclusive. Purchase prices range from $372.29 to $373.27 per share, inclusive. Purchase prices range from $373.30 to $374.28 per share, inclusive. Purchase prices range from $374.31 to $375.24 per share, inclusive. Purchase prices range from $375.36 to $376.34 per share, inclusive. Purchase prices range from $376.36 to $377.34 per share, inclusive. Purchase prices range from $377.36 to $378.35 per share, inclusive. Purchase prices range from $378.37 to $379.36 per share, inclusive. Purchase prices range from $379.38 to $379.80 per share, inclusive. Exhibit 24 - Power of Attorney (incorporated herein by reference to Exhibit 24 to Form 4 filed by the Reporting Person with the SEC on February 3, 2016, with respect to Alnylam Pharmaceuticals, Inc.). /s/ Alexandra Roger, attorney-in-fact 2017-01-13